Interaction between free fatty acids and glucose metabolism

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 5, Issue 5, 2002, Pages 545-549

  Boden, Guenther ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

FFA; Insulin resistance; Type 2 diabetes

Indexed keywords

DIACYLGLYCEROL; FATTY ACID; INSULIN; ISOPROTEIN; PROTEIN KINASE C; TRIACYLGLYCEROL; GLUCOSE;

CONTROLLED STUDY; FATTY ACID ANALYSIS; GLUCOSE METABOLISM; GLYCOGENOLYSIS; HUMAN; HUMAN CELL; INDUSTRIALIZATION; INSULIN RESISTANCE; INSULIN RESPONSE; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; REVIEW; UNITED STATES; BLOOD; GLUCOSE BLOOD LEVEL; LIVER; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION; SKELETAL MUSCLE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MUSCLE, SKELETAL; OBESITY;

EID: 0036725464     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200209000-00014     Document Type: Review

References (65)

1. Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res 1994; 35:177-193.
2. Felber JP, Magneanat G, Casthelaz M, et al. Carbohydrate and lipid oxidation in normal and diabetic subjects. Diabetes 1977; 26:693-699.
3. Boden G. Fuel metabolism in pregnancy and in gestational diabetes mellitus. Obstet Gynceol Clin North Am 1996; 23:1-10.
4. Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. J Clin Invest 1997; 100:1166-1173.
5. Sims EA, Danforth E, Norton ES, et al. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res 1973; 29:457-496.
6. Beck-Nielsen H, Pederson O, Lindskov HO. Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol (Copenh) 1979; 90:103-112.
7. Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss. J Clin Invest 1988; 82:1398-1406.
8. Gorden ES. Non-esterified fatty acids in blood of obese and lean subjects. Am J Clin Nutr 1960; 8:740-747.
9. Reaven GM, Hollenbeck C, Jeng C-Y, et al. Measurement of plasma glucose, free fatty acid, lactate and insulin for 24 h in patients with NIDDM. Diabetes 1988; 37:1020-1024.
10. Bergman RN, Mittelman SD. Central role of the adipocyte in insulin resistance. J Basic Clin Physiol Pharmacol 1998; 9:205-221.
11. Charles MA, Eschwege E, Thibult N, et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 1997; 40:1101-1106.
12. Paolisso G, Tataranni PA, Foley JE, et al. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995; 38:1213-1217.
13. Boden G, Jadali F, White J, et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 1991; 88:960-966.
14. Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995; 96:1261-1268.
15. Roden M, Price TB, Perseghin G, et al. Mechanisms of free fatty acid induced insulin resistance in humans. J Clin Invest 1996; 17:2859-2865.
16. Sivan E, Homko CJ, Whittaker PG, et al. Free fatty acids and insulin resistance during pregnancy. J Clin Endocrinol Metab 1998; 83:2338-2342.
17. Santomauro A, Boden G, Silva M, et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and non-diabetic subjects. Diabetes 1999; 48:1836-1841.
18. Reaven GM, Chang H, Ho H, et al. Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am J Physiol 1988; 254:E23-E30.
19. DeFronzo RA, Gunnarsson R, Bjorkman O, et al. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 1985; 76:149-155.
20. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1:785-789.
21. Boden G, Chen X, Ruiz J, et al. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93:2438-2440.
22. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103:253-259.
23. Storlien LH, Jenkins AB, Chisholm DJ, et al. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and ω-3 fatty acids in muscle phospholipid. Diabetes 1991; 40:280-289.
24. Pan DA, Lillioja S, Kriketos AD, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997; 46:983-988.
25. Koyama K, Chen G, Lee Y, Linger RH. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol 1997; 273:E708-E713.
26. Simoneau JA, Colberg SR, Thaete FL, Kelley DE. Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. FASEB J 1995; 9:273-278.
27. Phillips DIW, Caddy S, Ilic V, et al. Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism 1996; 45:947-950.
28. Oakes ND, Cooney GJ, Camilleri S, et al. Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 1997; 46:1768-1774.
29. Kim JK, Fillmore JJ, Chen Y, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 2001; 98:7522-7527. Fat accumulation in muscle causes insulin resistance in muscle, whereas fat accumulation in the liver causes insulin resistance in the liver.
30. Boden G, Lebed B, Schatz M, et al. Effects of acute changes of plasma FFA on intramuscular fat content and insulin resistance in healthy subjects. Diabetes 2001; 50:1612-1617. Acute elevations in plasma FFAs produce concurrently an increase in intramyocelluar triglyceride and a decrease in ISGU.
31. Farese RV. Protein kinase C. In: Olefsky J, Taylor SE, LeRoit D, editors. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott; 2000. pp. 239-251.
32. Bronfman M, Morales MN, Orellano A. Diacylglycerol activation of protein kinase C is modulated by long-chain acyl-CoA. Biochem Biophys Res Commun 1988; 152:987-992.
33. Nesher M, Boneh A. Effect of fatty acids and their acyl-CoA esters on protein kinase C activity in fibroblasts: possible implications in fatty acid oxidation defects. Biochim Biophys Acta 1994; 1221:66-72.
34. Chin JE, Dickens M, Tavare JM, Roth RA. Overexpression of protein kinase C isoenzymes alpha, beta I, gamma and episilon in cells overexpressing the insulin receptor. Effects on receptor phosphorylation and signaling. J Biol Chem 1993; 268:6338-6347.
35. DeFea K, Roth RA. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem 1997; 272:31400-31406.
36. Ravichandran LV, Esposito DL, Chen J, Quon MJ. Protein kinase C-ζ phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin. J Biol Chem 2000; 276:3543-3549.
37. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C and Iκ-B-α. Diabetes 2002; 51:2005-2011. Acute elevation in plasma FFAs results in large increases in diacylglycerol concentration, a sharp decrease in IκB-α concentration, and activation of protein kinase C (β and δ isoforms) in human skeletal muscle. These changes occur concurrently with development of insulin resistance (decrease in ISGU).
38. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade. Diabetes 1999; 48:1270-1274.
39. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46:3-10.
40. Chen X, Igbal N, Boden G. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 1999; 103:365-372.
41. Roden M, Stingl H, Chandramouli V, et al. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 2000; 49:701-707.
42. Boden G, Jadali F. Effects of lipid on basal carbohydrate metabolism. Diabetes 1991; 40:686-692.
43. Jenssen T, Nurjhan N, Consoli A, Gerich JE. Failure of substrate-induced gluconeogenesis to increase overall glucose appearance in normal humans: a demonstration of hepatic autoregulation without a change in plasma glucose concentration. J Clin Invest 1990; 86:489-497.
44. Boden G, Chen X, Capulong E, Mozzoli M. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 2001; 50:810-816. In 20-h fasted patients with type 2 diabetes mellitus, the decrease in gluconeogenesis (caused by nicotinic acid induced decrease in plasma FFAs) was not associated with an increase in glycogenolysis.
45. Magnusson I, Rothman DL, Katz LD, et al. Increased rate of gluconeogenesis in type II diabetes mellitus. J Clin Invest 1992; 90:1323-1327.
46. Edgerton DS, Cardin S, Emshwiller M, et al. Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes 2001; 50:1872-1882. In dogs, insulin suppresses endogenous glucose production primarily by inhibiting glycogenolysis.
47. Gastaldelli A, Toschi E, Pettiti M, et al. Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 2001; 50:1807-1812. In diabetic and nondiabetic persons, insulin suppresses EGP primarily by inhibition of glycogenolysis.
48. Boden G, Cheung P, Stein TP, et al. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol 2002; 283:E12-E19. In healthy human persons, FFAs cause hepatic insulin resistance by interfering with insulin suppression of glycogenolysis.
49. Ferrannini E, Barrett E, Bevilacqua S, et al. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983; 72:1737-1747.
50. Rigalleau V, Binnert C, Minehira K, et al. In normal men, free fatty acids reduce peripheral but not splanchnic glucose uptake. Diabetes 2001; 50:727-732.
51. Fanelli C, Calderone S, Epifano L, et al. Demonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans. J Clin Invest 1993; 92:1617-1622.
52. Stumvoll M, Chintalapudi U, Perriello G, et al. Uptake and release of glucose by the human kidney: postabsorptive rates and responses to epinephrine. J Clin Invest 1995; 96:2528-2533.
53. Ryysy L, Hakkinen A-M, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49:749-758.
54. Boden G, Chen X, Stein TP. Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2001; 208:E23-E30. Gluconeogenesis and EGP are increased only in patients with type 2 diabetes who are more than mildly insulin deficient, and this probably represents a late event in the course of the disease.
55. Felber JP, Vanotti A. Effects of fat infusions on glucose tolerance and plasma insulin levels. Med Exp 1964; 10:153-156.
56. Crespin SR, Greenough WB, Steinberg D. Stimulation of insulin secretion by long-chain free fatty acids. J Clin Invest 1973; 52:1979-1984.
57. Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and β-cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 1990; 127:1580-1589.
58. Zhou Y-P, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 1994; 93:870-876.
59. Bollheimer LC, Skelly RH, Chester MW, et al. Chronic exposure to free fatty acids reduced pancreatic β cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthesis translation. J Clin Invest 1998; 101:1094-1101.
60. Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 1995; 44:1239-1242.
61. Boden G, Chen X, Iqbal N. Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects. Diabetes 1998; 47:1609-1612.
62. Boden G. Free fatty acids (FFA), a link between obesity and insulin resistance. Front Biosci 1998; 3:D169-D175.
63. Boden G, Chen X. Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes 1999; 48:577-583.
64. Reaven GM. Role of insulin resistance in human disease. Diabetes 1998; 37:1595-1607.
65. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 34:115-120.